**Core tip:** Necrolytic acral erythema (NAE) is a rare dermatological entity associated with hepatitis C virus (HCV) and zinc deficiency. Aim of the case report is to describe the occurrence of NAE in a human immunodeficiency virus/HCV coinfected patient, elucidate the clinical characteristics, pathophysiologic mechanisms and increase clinician awareness about diagnosis and management.

INTRODUCTION
============

Necrolytic acral erythema (NAE) is a rare dermatological entity. While the disease is frequently associated with hepatitis C virus (HCV) infection or zinc deficiency\[[@B1]-[@B4]\], the pathogensis is poorly understood. NAE is characterized by erythematous lesions, violaceous papules, bullae and superficial skin erosions occurring primarily in the lower extremities and dorsal feet. Associated symptoms include pruritus, pain, burning and dysesthesia. NAE is an infrequent extrahepatic manifestation of hepatitis C with a much less frequent overall prevalence of 1.7% compared to cryoglobulinemia, porphyria cutanea tarda, lichen planus\[[@B5],[@B6]\]. Additionally, NAE has been reported in patients with zinc deficiency and less frequently in association with vaccination against hepatitis B\[[@B2],[@B7]\]. NAE should be differentiated from psoriasis and eczematous dermatitis, lichen simplex chronicus, hypertrophic lichen planus, acrokeratoelastoidosis, and acrokeratosis paraneoplastica. Zinc supplementation and treatment of underlying hepatitis C have been related to favorable response. We describe a case of a patient with human immunodeficiency virus (HIV) and hepatitis C co-infections diagnosed with NAE.

CASE PRESENTATION
=================

Chief complaints and history of past illness
--------------------------------------------

A 66-year-old woman, with past medical history of well-controlled HIV infection on antiretroviral (ARV) therapy with azatanavir/ritonavir and abacavir/lamivudine and untreated chronic hepatitis C (Genotype 1b) with cirrhosis, who presented with chief complaint of painless, non-pruritic rash for one week. The rash began as diffuse, patchy erythematous lesions of bilateral lower extremities, starting at her feet but progressing up her legs to her thighs. She noted associated edema, but denied fevers, chills, joint pain, oral lesions or ulcers and weakness or numbness in her extremities. She was not sexually active and denied any allergies. Patient was recently discharged from the hospital after a COPD exacerbation. She was discharged on a brief oral prednisone taper, which she completed prior to presentation, but was still taking when the rash developed. On admission patient was afebrile and hemodynamically stable.

Physical examination upon admission
-----------------------------------

Her physical exam revealed dusky erythematous patches of non-blanching palpable petechiae and purpura on bilateral calves and thighs as well as on her right forearm. She also had vesiculobullous lesions on bilateral lower extremities with several scattered erosions, without lesions on palms or soles and no oral or genital lesions (Figure [1](#F1){ref-type="fig"}). Nikolsky sign was negative. Patient underwent extensive work-up for possible rheumatologic disorders including vasculitis and cryoglobulinemia.

![Typical appearance of necrolytic acral erythema involving the right upper and right and left lower extremities.](WJH-11-226-g001){#F1}

Laboratory examinations
-----------------------

Laboratory findings are shown in Table [1](#T1){ref-type="table"}. Dermatology consulted during her hospital stay and performed punch skin biopsies of right and left thigh. Pathology reported thickened parakeratotic stratum corneum most consistent with NAE (Figure [2](#F2){ref-type="fig"}).

###### 

Basic laboratory findings

  **Parameters**                        **Reference range**
  ------------------------------------- ---------------------
  White blood cell count - 15.3         4.5-11 K/uL
  Hematocrit - 44.5                     34%-47%
  Hemoglobin -- 13.6                    11.7-15 g/dL
  Platelet count -- 376000              150-450 K/uL
  Blood urea nitrogen - 42              7-20 mg/dL
  Creatinine -- 1.28                    0.5-1.1 mg/dL
  AST - 17                              \< 36 U/L
  ALT - 23                              \< 46 U/L
  Total bilirubin - 2.0                 0.1-1.2 mg/dL
  Direct bilirubin -- 1.0               \< 0.9 mg/dL
  gGT - 145                             0-60 IU/L
  Total protein -- 6.4                  6-8.3 g/dL
  Albumin -- 2.6                        3.5-5.0 g/dL
  Erythrocyte Sedimentation rate - 68   (0-24 mm/h)
  C-reactive protein -- 78.32           \< 5.1 mg/L
  INR -- 1.0                            0.9-1.1
  C3 - 156                              90-180 mg/dL
  cANCA - negative                      Negative
  pANCA - negative                      Negative
  Rheumatoid factor - \< 15             0-15 IU/mL
  Anti-SSA -- negative                  Negative
  Anti-SSB -- negative                  Negative
  Anti-CCP -- negative                  Negative
  RPR -- non-reactive                   Non-reactive
  Cryoglobulins -- negative             Negative
  Antinuclear antibodies - negative     Negative
  AntidsDNA -- negative                 Negative
  HIV RNA -- undetectable               \< 20 copies/mL
  CD4 -- 564/25%                        Cells/mL
  HCV-RNA -- 346755 genotype 1B         \< 15 IU/mL

HCV: Hepatitis C virus; HIV: Human immunodeficiency virus; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; INR: International normalized ratio; cANCA: Cytoplasmic anti-neutrophil cytoplasmic antibody; pANCA: Perinuclear anti-neutrophil cytoplasmic antibody; CCP: Cyclic citrullinated peptides; RPR: Rapid plasma regain.

![Low and high power of skin histopathology demonstrating bullous/hemorrhagic cellulitis with thick parakeratosis, impetiginization of the dermis and rare scattered neutrophilic infiltrates with dermal hemorrhage.](WJH-11-226-g002){#F2}

FINAL DIAGNOSIS
===============

NAE in an HIV/HCV co-infected patient.

TREATMENT
=========

Patient was started on prednisone 20 mg daily along with zinc supplementation given her low serum zinc levels. She had resolution of her vesiculobullous lesions and improvement of erythema. Unfortunately, no clinical images were obtained after her clinical improvement.

OUTCOME AND FOLLOW-UP
=====================

Patient was discharged to follow-up with her infectious diseases provider for initiation of hepatitis C treatment. She was initiated on sofosbuvir/veltapasvir and her ARV was transitioned to bictegravir/emtricitabine/tenofovir alafenamide to avoid any drug drug interactions.

DISCUSSION
==========

Necrolytic erythemas include NAE, necrolytic migratory erythema, acrodermatitis enteropathica, and various dermopathies due to nutrient deficiencies\[[@B8]\]. NAE was first described by El-Ghandour et al\[[@B4]\] in a cohort of Egyptian patients. NAE is observed most commonly in women and with age of onset around 40 years\[[@B2]\]. In early stages, skin changes consist of erythematous papules and plaques with early skin erosion. During the second stage, there is increasing thickness of the papules and lichenification followed by hyperpigmentation often associated with necrosis of superficial epidermis. In the late stage hyperpigmentation becomes more prominent. The most common location of lesions is the back of the feet and toes, and also in lower extremities along the surface of the Achilles tendon, the malleoli, legs and knees. Histological characteristics include acanthosis, spongiosis in early stages of the disease process along with psoriasiform hyperplasia in the later stages. In advanced disease, parakeratosis and possible necrosis of keratinocytes can be seen. These histopathological findings are non-specific and high clinical suspicion is required for early diagnosis\[[@B9]\].

The pathogenesis of NAE is unknown and several mechanisms have been proposed. Potential etiologies include the metabolic changes associated with liver dysfunction and diabetes\[[@B10]-[@B12]\]. Hypoalbuminemia, hypoaminoacidemia and hyperglucagonemia are all associated with inducing inflammatory responses\[[@B13]\].

Other proposed mechanisms include mineral deficiencies, primarily zinc. Moneib et al\[[@B10]\] reported that serum levels of zinc are low in patients with NAE. Zinc deficiency causes a reduction in serum transport proteins, such as retinol-binding protein and prealbumin, which impair delivery of the vitamin A, major factor for epidermal proliferation and differentiation\[[@B9]\]. The significance of zinc deficiencies in NAE is further limited by the role of blood measurements for the detection of zinc. Determination levels of zinc levels in future patients with NAE is indicated\[[@B11],[@B12]\].

Additional association has been reported in the setting of hepatitis C. Hepatitis C viral load and genotype may be related to the etiopathogenesis of NAE\[[@B13],[@B14]\]. Although no clear correlation with genotype has been reported in the literature, most article reports describe patients with genotypes 1 and 4\[[@B5]\]. Moreover, in setting of HCV, it seems that there is correlation between severity of lesions and liver damage. While the exact role of zinc deficiency in NAE is unknown and controversial\[[@B12]\].

The treatment of NAE is challenging due to the lack of available data. There are no prospective randomized control trials regarding optimal treatment and most available information is provided from retrospective case series. Regarding treatment of NAE lesions after zinc supplementation, the current literature data are inconsistent. Oral zinc supplementation showed a variable response rate. Zinc with topical tacrolimus, vitamin B1, and vitamin B6 subcutaneous interferon alpha was also reported with variable rates of response and inconsistent benefits\[[@B8]\].

Similarly, there are controversial data about topical or systemic corticosteroids, and zinc supplementation ranging from no response to complete resolution\[[@B1]\]. A trial of brief systemic steroids and oral zinc supplementation and close monitoring for clinical resolution is usually warranted in patients with clinical manifestations of NAE regardless of the serum zinc levels.

In HCV-associated NAE complete or partial resolution has been demonstrated previously with interferon alpha-2b and/or ribavirin, and also with combinations of interferon α-2b and zinc\[[@B8]\]. Interferon free direct acting antiviral regimens have also been shown to be effective and should be offered to chronic HCV patients with the goal of sustained viral response.

It is interesting to note that zinc dysregulation and metabolic alterations can also occur as a result of hepatitis C and HIV infections\[[@B2]\], but to our knowledge case reports of NAE in HCV/HIV co-infected patients are rare. Najarian et al\[[@B12]\] reported a case of NAE in a woman with well controlled HIV and untreated HCV. Patient presented with well-demarcated, painful, pruritic plaques with a distinctive erythematous rim and a distinctive sandal-like pattern of bilateral lower extremities. She was found to have low zinc levels and was treated successfully with oral zinc supplementation. One of the proposed mechanisms for the pathogenesis of NAE in co-infected patients is the increased zinc loss with urine that can be observed with both HCV and HIV. In our patient, urine zinc levels were not routinely checked, and zinc levels after treatment with zinc supplementation were not available.

It is well known that patients with HIV/HCV co-infection have accelerated fibrosis progression due to multiple mechanisms and perhaps this may play a role in NAE. In addition these patients have higher levels of pro-inflammatory cytokines such as TGF-beta and IFN gamma along with higher levels of lipopolysacchrides which all can enhance inflammatory response. Perhaps this also plays a role in NAE in HIV/HCV co-infected patients.

In terms of appearance of lesions and distribution, there is no significant difference in HCV/HIV co-infected versus mono-infected patients with HCV, or in seronegative patients with isolated zinc deficiency. Skin biopsy can be a powerful tool, but given characteristics of skin lesions, NAE can also be a clinical diagnosis. Table [2](#T2){ref-type="table"} describes the reported cases of NAE, the serologic profiles of patients, and the methods of diagnosis and treatment.

###### 

Literature review -- cases of necrolytic acral erythema

                                   **HCV**   **HIV**   **Zinc deficiency**   **Diagnosis**        **Treatment**
  -------------------------------- --------- --------- --------------------- -------------------- ------------------------------------------------
  Srisuwanwattana et al\[[@B1]\]   Yes       NA        No                    Skin biopsy          Zinc supplementation and topical steroids
  Kapoor et al\[[@B2]\]            Yes       NA        Yes                   Clinical diagnosis   Oral zinc supplementation
  Jakubovic et al\[[@B3]\]         No        NA        Yes                   Skin biopsy          Nutritional Supplementation
  Abdallah et al\[[@B5]\]          Yes       NA        No                    Skin biopsy          Zinc supplementation
  Pernet et al\[[@B7]\]            No        NA        No                    Skin biopsy          Resolved spontaneously
  Tabibian et al\[[@B8]\] Case 1   Yes       NA        Yes                   Skin biopsy          Zinc supplementation
  Tabibian et al\[[@B8]\] Case 2   Yes       NA        Yes                   Skin biopsy          Zinc supplementation
  Das et al\[[@B9]\]               No        NA        NA                    Skin biopsy          Zinc supplementation
  Najarian et al\[[@B12]\]         Yes       Yes       Yes                   Skin biopsy          Zinc supplementation
  Shumez et al\[[@B15]\]           Yes       NA        Yes                   Skin biopsy          Zinc supplementation
  Shaikh et al\[[@B16]\]           Yes       NA        No                    Skin biopsy          Ledipasvir/sofosbuvir
  Wu et al\[[@B17]\]               No        NA        NA                    Skin biopsy          Systemic steroids
  Rahman et al\[[@B18]\]           Yes       NA        NA                    Skin biopsy          Systemic steroids and zinc supplementation
  Botelho et al\[[@B19]\]          Yes       NA        Yes                   Skin biopsy          Zinc supplementation
  Panta et al\[[@B20]\]            No        NA        Low normal levels     Skin biopsy          Oral zinc supplementation and topical steroids
  Pandit et al\[[@B21]\] Case 1    No        NA        Yes                   Skin biopsy          Oral zinc supplementation
  Pandit et al\[[@B21]\] Case 2    No        NA        Yes                   Clinical diagnosis   Oral zinc supplementation

NA: Not available; HCV: Hepatitis C virus; HIV: Human immunodeficiency virus.

The early diagnosis of NAE is crucial, regardless of the underlying disorder, and early and effective treatment can improve patients quality of life and limit secondary infections through skin lesions. The interpretation of skin histopathology should be performed by experienced pathologists, in order to avoid misinterpretation of the results. Kapoor et al\[[@B2]\] reported a case of NAE in a 44-year-old man with history of HCV, who had findings consistent with eczema or psoriasis on skin biopsy. Patient received multiple courses of treatment with immunosuppressants without significant improvement, was hospitalized multiple times with episodes of cellulitis and suicidal ideation, and after nine years he was treated successfully with oral zinc supplementation with improvement of lesions, pain and functional status\[[@B4]\].

CONCLUSION
==========

NAE as a rare skin disorder often represents clinical manifestation of underlying and frequently undiagnosed hepatitis C. The etiology is likely multifactorial, as demonstrated in our patient who had both untreated hepatitis C cirrhosis as well as documented zinc deficiency. This case highlights the importance of clinical recognition of NAE and early skin biopsy to confirm the diagnosis. Additionally, this case provides further cause for the expedient treatment of HCV, particularly in HIV/HCV co-infected patients. High clinical suspicion, physician awareness and early diagnosis play a pivotal role in appropriate management and optimal clinical outcomes.
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